Abstract
Hyperglycemia is the major cause of diabetic angiopathy. Sarpogrelate hydrochloride is an antiplatelet drug, and expected to be useful in the treatment of chronic arterial occlusive diseases. The aim of our study was to evaluate the possible effects of sarpogrelate hydrochloride on adhesion molecule expression and its underlying mechanism in the prevention and treatment of cardiovascular disorders. Intercellular adhesion molecule-1 (ICAM-1) expression and superoxide dismutase (SOD) activity were determined after endothelial cells were exposed to high glucose in the absence and presence of sarpogrelate hydrochloride. Coincubation of endothelial cells with high glucose for 24 h resulted in a significant increase of monocyte–endothelial cell adhesion and the expression of ICAM-1 (P < 0.01). These effects were abolished by sarpogrelate hydrochloride and sarpogrelate hydrochloride significantly increased SOD activities (40 ± 8 vs. 47 ± 7, n = 8, P < 0.01). The low dose sarpogrelate group (0.1 μM) had significantly higher monocyte–endothelial cell adhesion and the expression of ICAM-1 than medium dose sarpogrelate group (1.0 μM) and high dose sarpogrelate group (10.0 μM) (P < 0.05 for comparison among three groups and P < 0.01 for difference between low and high dose sarpogrelate groups). These findings suggested that sarpogrelate hydrochloride was able to protect vascular endothelium from dysfunction induced by high glucose.
Similar content being viewed by others
References
Malakul W, Thirawarapan S, Suvitayavat W, Woodman OL (2008) Type 1 diabetes and hypercholesterolaemia reveal the contribution of endothelium-derived hyperpolarizing factor to endothelium-dependent relaxation of the rat aorta. Clin Exp Pharmacol Physiol 35:192–200
McNulty PH, Tulli MA, Robertson BJ, Lendel V, Harach LA, Scott S, Boehmer JP (2007) Effect of simulated postprandial hyperglycemia on coronary blood flow in cardiac transplant recipients. Am J Physiol Heart Circ Physiol 293:H103–H108
Narendhirakannan RT, Subramanian S, Kandaswamy M (2006) Biochemical evaluation of antidiabetogenic properties of some commonly used Indian plants on streptozotocin-induced diabetes in experimental rats. Clin Exp Pharmacol Physiol 33:1150–1157
Sorensen VR, Mathiesen ER, Clausen P, Flyvbjerg A, Feldt-Rasmussen B (2005) Impaired vascular function during short-term poor glycaemic control in type 1 diabetic patients. Diabet Med 22:871–876
Ceriello A, Kumar S, Piconi L, Esposito K, Giugliano D (2007) Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care 30:649–654
De Mattia G, Bravi MC, Laurenti O, Moretti A, Cipriani R, Gatti A, Mandosi E, Morano S (2008) Endothelial dysfunction and oxidative stress in type 1 and type 2 diabetic patients without clinical macrovascular complications. Diabetes Res Clin Pract 79:337–342
Van Dam B, van Hinsbergh VW, Stehouwer CD, Versteilen A, Dekker H, Buytenhek R, Princen HM, Schalkwijk CG (2006) Vitamin E inhibits lipid peroxidation-induced adhesion molecule expression in endothelial cells and decreases soluble cell adhesion molecules in healthy subjects. Cardiovasc Res 57:563–571
Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801–809
Ross R (1999) Atherosclerosis: an inflammatory disease. New Engl J Med 340:115–126
Jagroop IA, Mikhailidis DP (2001) Doxazosin, an α1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets. J Hum Hypertens 15:203–207
Hasegawa Y, Suehiro A, Higasa S, Namba M, Kakishita E (2002) Enhancing effect of advanced glycation end products on serotonin-induced platelet aggregation in patients with diabetes mellitus. Thromb Res 107:319–323
Nagatomo T, Rashid M, Abul Muntasir H, Komiyama T (2004) Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther 104:59–81
Ozawa H, Abiko Y, Akimoto T (2003) A 50-year history of new drugs in Japan—the development and trends of hemostatics and antithrombotic drugs. Yakushigaku Zasshi 38:93–105
Uchiyama S, Ozaki Y, Satoh K, Kondo K, Nishimaru K (2007) Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose–response study. Cerebrovasc Dis 24:264–270
Doggrell SA (2004) Sarpogrelate: cardiovascular and renal clinical potential. Expert Opin Investig Drugs 13:865–874
Gong H, Nakamura T, Hattori K, Ohnuki T, Rashid M, Nakazawa M, Watanabe K, Nagatomo T (2000) A novel 5-HT2 antagonist, sarpogrelate hydrochloride, shows inhibitory effects on both contraction and relaxation mediated by 5-HT receptor subtypes in porcine coronary arteries. Pharmacology 61:263–268
Nonogaki K, Nozue K, Oka Y (2006) Increased hypothalamic 5-HT2A receptor gene expression and effects of pharmacologic 5-HT2A receptor inactivation in obese Ay mice. Biochem Biophys Res Commun 351:1078–1082
Borghi MO, Panzeri P, Shattock R, Sozzani S, Dobrina A, Meroni PL (2000) Interaction between chronically HIV-infected promonocytic cells and human umbilical vein endothelial cells: role of proinflammatory cytokines and chemokines in viral expression modulation. Clin Exp Immunol 120:93–100
Dorffel Y, Latsch C, Stuhlmuller B, Schreiber S, Scholze S, Burmester GR, Scholze J (1999) Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 34:113–117
Hiraoka M, Nitta N, Nagai M, Shimokado K, Yoshida M (2004) MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway. Life Sci 75:1333–1341
Rothlein R, Czajkowski M, O’Neill MM, Marlin SD, Mainolfi E, Merluzzi VJ (1988) Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines. Regulation by pharmacologic agents and neutralizing antibodies. J Immunol 141:1665–1669
Carmeli E, Maor M, Kodesh E (2009) Expression of superoxide dismutase and matrix metalloproteinase type 2 in diaphragm muscles of young rats. J Physiol Pharmacol 60:31–36
Liang KW, Lee WJ, Lee WL, Chen YT, Ting CT, Sheu WH (2008) Diabetes exacerbates angiographic coronary lesion progression in subjects with metabolic syndrome independent of CRP levels. Clin Chim Acta 388:41–45
Lei H, Venkatakrishnan A, Yu S, Kazlauskas A (2007) Protein kinase A-dependent translocation of Hsp90 alpha impairs endothelial nitric-oxide synthase activity in high glucose and diabetes. J Biol Chem 282:9364–9371
Vane JR, Anggard EE, Botting RM (1990) Regulatory functions of the vascular endothelium. N Engl J Med 323:27–36
McDuffie JE, Motley ED, Limbird LE, Maleque MA (2000) 5-Hydroxytryptamine stimulates phosphorylation of p44/p42 mitogen-activated protein kinase activation in bovine aortic endothelial cell cultures. J Cardiovasc Pharmacol 35:398–402
Saini HK, Takeda N, Goyal RK, Kumamoto H, Arneja AS, Dhalla NS (2004) Therapeutic potentials of sarpogrelate in cardiovascular disease. Cardiovasc Drug Rev 22:27–54
Doggrell SA (2004) Sarpogrelate: cardiovascular and renal clinical potential. Expert Opin Investig Drugs 13:865–874
Hara H, Osakabe M, Kitajima A, Tamao Y, Kikumoto R (1991) MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. Thromb Haemost 65:415–420
Fujita M, Minamino T, Sanada S, Asanuma H, Hirata A, Ogita H, Okada K, Tsukamoto O, Takashima S, Tomoike H, Node K, Hori M, Kitakaze M (2004) Selective blockade of serotonin 5-HT2A receptor increases coronary blood flow via augmented cardiac nitric oxide release through 5-HT1B receptor in hypoperfused canine hearts. Mol Cell Cardiol 37:1219–1223
Iwabayashi M, Taniyama Y, Sanada F, Azuma J, Iekushi K, Kusunoki H, Chatterjee A, Okayama K, Rakugi H, Morishita R (2012) Atherosclerosis 220:337–342
Miyazaki M, Higashi Y, Goto C, Chayama K, Yoshizumi M, Sanada H, Orihashi K, Sueda T (2007) Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease. J Cardiovasc Pharmacol 49:221–227
Yamada K, Niki H, Nagai H, Nishikawa M, Nakagawa H (2012) Serotonin potentiates high-glucose-induced endothelial injury: the role of serotonin and 5-HT(2A) receptors in promoting thrombosis in diabetes. J Pharmacol Sci 119:243–250
Miyata K, Shimokawa H, Higo T, Yamawaki T, Katsumata N, Kandabashi T, Tanaka E, Takamura Y, Yogo K, Egashira K, Takeshita A (2000) Sarpogrelate, a selective 5-HT2A serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model. J Cardiovasc Pharmacol 35:294–301
Kodama A, Komori K, Hattori K, Yamanouchi D, Kajikuri J, Itoh T (2009) Sarpogrelate hydrochloride reduced intimal hyperplasia in experimental rabbit vein graft. J Vasc Surg 49:1272–1281
Lin SJ, Shyue SK, Shih MC, Chu TH, Chen YH, Ku HH, Chen JW, Tam KB, Chen YL (2007) Superoxide dismutase and catalase inhibit oxidized low-density lipoprotein-induced human aortic smooth muscle cell proliferation: role of cell-cycle regulation, mitogen-activated protein kinases, and transcription factors. Atherosclerosis 190:124–134
Lin SJ, Shyue SK, Hung YY, Chen YH, Ku HH, Chen JW, Tam KB, Chen YL (2005) Superoxide dismutase inhibits the expression of vascular cell adhesion molecule-1 and intracellular cell adhesion molecule-1 induced by tumor necrosis factor-alpha in human endothelial cells through the JNK/p38 pathways. Arterioscler Thromb Vasc Biol 25:334–340
Acknowledgments
This study was supported by a grant from the Education Department of Heilongjiang Province (11551201), Youth Science Foundation of Heilongjiang Province (QC2010080) and National Natural Science Foundation of China (81100574).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Su, Y., Mao, N., Li, M. et al. Sarpogrelate inhibits the expression of ICAM-1 and monocyte–endothelial adhesion induced by high glucose in human endothelial cells. Mol Cell Biochem 373, 195–199 (2013). https://doi.org/10.1007/s11010-012-1490-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-012-1490-9